Pazopanib-Induced Alopecia, an Underestimated Toxicity? by Andrea Biondo et al.
ORIGINAL RESEARCH
published: 11 May 2015
doi: 10.3389/fonc.2015.00112
Edited by:
Alexandre Arcaro,
University of Bern, Switzerland
Reviewed by:
Simon Chowdhury,
Guy’s Hospital London, UK
Lawrence Panasci,
Jewish General Hospital, Canada
*Correspondence:
James Larkin,
Royal Marsden Hospital, Fulham
Road, London SW3 6JJ, UK
james.larkin@rmh.nhs.uk
Specialty section:
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal Frontiers in
Oncology
Received: 05 February 2015
Accepted: 27 April 2015
Published: 11 May 2015
Citation:
Biondo A, Alexander H, Khabra K,
Pickering L, Gore M and Larkin J
(2015) Pazopanib-induced alopecia,
an underestimated toxicity?
Front. Oncol. 5:112.
doi: 10.3389/fonc.2015.00112
Pazopanib-induced alopecia, an
underestimated toxicity?
Andrea Biondo, Helen Alexander, Komel Khabra, Lisa Pickering, Martin Gore and
James Larkin*
Royal Marsden Hospital, London, UK
Pazopanib and sunitinib are treatment options for metastatic renal cell cancer (mRCC),
with similar efficacy, and minor differences in their toxicity profile. Our experience has
suggested that pazopanib-induced alopecia may be a potentially significant but previously
under-reported toxicity. For this reason, we performed a retrospective review of the clinical
records of all patients with mRCC treated with pazopanib at the Royal Marsden Hospital
from European licensing until June 2013, and all patients treated with sunitinib over the
same period. We found that 36 patients with mRCC were treated with pazopanib and 85
patients with sunitinib. Four of the 36 (11%) patients treated with pazopanib developed
alopecia severe enough to warrant a wig versus none of 85 patients treated with
sunitinib (p=0.007). In conclusion, grade 2 pazopanib-induced alopecia was reported
at significantly higher rates when compared to sunitinib-induced alopecia. Hence, in
our view, patients should be informed about this potential toxicity when discussing the
treatment options for mRCC.
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Introduction
Pazopanib and sunitinib are both approved first line treatments for metastatic renal cell cancer
(mRCC) (1). They appear to have similar efficacy, with minor differences in their toxicity profile
(2, 3). In the PISCES study, a randomized double-blind cross-over trial, patients showed a preference
for pazopanib because of less fatigue and better overall quality of life. The COMPARZ study, a
randomized open-label trial of pazopanib versus sunitinib in the first line treatment of mRCC,
showed non-inferiority of progression-free survival (PFS) with pazopanib and favored its quality
of life and safety profiles. In current clinical practice, the choice of treatment is at the discretion of
the treating physician and patient.
Anti-cancer treatment-induced alopecia may impact significantly on the quality of life of patients
(4). Anecdotal evidence in our practice has suggested that pazopanib-induced alopecia may be a
potentially significant but previously under-reported toxicity. We therefore retrospectively analyzed
rates of pazopanib-induced alopecia, severe enough to warrant a wig [i.e., Common Terminology
Criteria for Adverse Events (CTCAE) grade 2; Table 1], in comparison to the rates of sunitinib-
induced alopecia in patients treated for mRCC.
Materials and Methods
We performed a retrospective review of the clinical records of all patients with mRCC treated with
pazopanib at the Royal Marsden Hospital from European licensing until June 2013, and all patients
treated with sunitinib over the same period. Fisher’s exact statistical test was used to compare the
two groups, and the Kaplan–Meier method and log rank test for PFS analysis. PFS was defined as
the date of starting treatment to the date of progression.
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TABLE 1 | Alopecia grading, adapted from CTCAE criteria (5).
Adverse
event
Grade
1 2 3 4 5
CTCAE v3.0
Alopecia Thinning or patchy Complete – – –
CTCAE v4.0
Alopecia Hair loss of <50% of
normal for that individual
that is not obvious from
a distance but only on
close inspection; a
different hair style may
be required to cover the
hair loss but it does not
require a wig or hair
piece to camouflage
Hair loss of 50%
normal for that
individual that is readily
apparent to others; a
wig or hair piece is
necessary if the patient
desires to completely
camouflage the hair
loss; associated with
psychosocial impact
– – –
Results
Thirty-six (F= 13, M= 23; median age 64.8 years) patients with
mRCCwere treatedwith pazopanib and followedup fromNovem-
ber 2010 to June 2013, and eighty-five (F= 26, M= 59; median
age 66.2 years) patients with mRCC were treated with sunitinib
over the same period. Four of the 36 (11%) patients treated with
pazopanib followed up at the Royal Marsden developed alopecia
severe enough to warrant a wig (Figure 1) versus none of 85
patients treated with sunitinib (p= 0.007). All four patients who
developed alopecia while on pazopanib were females (31% of
females on pazopanib), aged 88, 75, 70, and 67 years at the start
of treatment. None of the four patients had any reported degree of
alopecia at baseline and none had significant thyroid dysfunction
while on therapy. The median time for the development of alope-
cia while on pazopanib was 6.5months (range 4.7–18.3) from the
start of therapy. Patients a, b, and c did not receive any radiother-
apy to the brain, but patient d started treatment with pazopanib
in October 2012 and had treatment with Cyberknife radiosurgery
at the same time (20Gy in one fraction to three right temporal
lobe lesions) and in February 2014 (24Gy in one fraction to a right
frontal lobe lesion). Alopecia was first noted in March 2013. If we
exclude patient d from the analysis, the difference in pazopanib-
induced alopecia versus sunitinib remains statistically significant.
ThemedianPFS onpazopanibwas 6.6months [95%confidence
interval (CI) 2.1–10.1] versus 5.3months on sunitinib (95% CI
3.4–7.8; p= 0.583).
Discussion
In this retrospective analysis, grade 2 pazopanib-induced alope-
cia was reported at significantly higher rates when compared to
sunitinib-induced alopecia.
FIGURE 1 | Timeline for the development of alopecia in 4 patients
treated with pazopanib.
The CTCAE are generally used in clinical trials to grade
the severity of adverse events, including drug-induced alopecia
(Table 1). In the COMPARZ study (3), comparing pazopanib
to sunitinib in the first line treatment of mRCC, patients were
followed up until death or withdrawal from the study. Patients in
the pazopanib group showed a statistically significant higher risk
of developing any grade of alopecia versus the sunitinib group (14
versus 8%). The grade 1 and 2 rates of alopecia were, however,
grouped together. In the PISCES study (2), patients were assessed
for adverse events over a 10-week period on each drug. Drug-
induced alopecia was not reported in this trial for either drug,
probably due to the short follow-up period on each drug.
In this retrospective study, we make the assumption that the
development of significant alopecia on treatment was accurately
recorded and that all potential confounding factors were consid-
ered. Cyberknife to the brain may cause a degree of alopecia. No
concomitant drugs recorded were deemed to be a likely cause for
the grade 2 alopecia.
In our analysis, the median time for development of alopecia
was 6.5months. The median PFS with pazopanib in our retro-
spective analysis was 6.6months. The median PFS reported in
the much larger COMPARZ study is 8.4months (3). This makes
pazopanib-induced alopecia a potentially clinically significant
chronic toxicity, whichmay have been thus far underestimated. In
our view, patients should be informed about this potential toxicity
when discussing the treatment options for mRCC.
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